Volume 35, Issue 7 (10-2024)
Studies in Medical Sciences 2024, 35(7): 579-585 |
Back to browse issues page
Ethics code: IR.IAU.YAZD.REC.1402.040
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Halvani A, Rafatmagham S, Poorahmadi A. INVESTIGATION OF EPIDEMIOLOGY AND CLINICAL MANIFESTATION OF TUBERCULOSIS BEFORE AND AFTER THE COVID-19 PANDEMIC IN YAZD. Studies in Medical Sciences 2024; 35 (7) :579-585
URL: http://umj.umsu.ac.ir/article-1-6334-en.html
URL: http://umj.umsu.ac.ir/article-1-6334-en.html
Department of Internal Medicine, Yazd Medical Science Branch, Islamic Azad University, Yazd, Iran , halvani47@yahoo.com
Abstract: (729 Views)
Background & Aims: Due to the similarity of symptoms between tuberculosis (TB) and COVID-19, distinguishing between these two diseases poses a significant challenge. This study aimed to investigate the epidemiology and clinical manifestations of TB in Yazd City before and after the COVID-19 pandemic.
Materials & Methods: This descriptive-analytical, cross-sectional study included all TB patients in Yazd City during the years 2018 and 2021 who were referred to the TB reference center for treatment. A total of 277 patients were selected through consecutive sampling, and data analysis was performed using SPSS software.
Results: In 2018, 128 patients (72 females and 56 males) were treated, compared to 149 patients (78 females and 71 males) in 2021. A comparison of clinical manifestations revealed a reduction in symptoms such as fever, cough, dyspnea, sputum production, night sweats, weight loss, appetite loss, chest pain, and fatigue. Among these, appetite loss, fatigue, and hospitalizations due to TB showed statistically significant reductions. The hospitalization rate for TB patients decreased following the onset of the pandemic. No significant differences were observed in the relative frequency, gender distribution, or treatment completion rates between the two years. Additionally, TB incidence and prevalence remained unchanged, and COVID-19 had no impact on the age or gender distribution of TB patients.
Conclusion: The findings indicate a reduction in hospitalizations and certain clinical symptoms of TB during the COVID-19 pandemic, highlighting the need for greater attention to TB, particularly in cases involving other comorbidities.
Materials & Methods: This descriptive-analytical, cross-sectional study included all TB patients in Yazd City during the years 2018 and 2021 who were referred to the TB reference center for treatment. A total of 277 patients were selected through consecutive sampling, and data analysis was performed using SPSS software.
Results: In 2018, 128 patients (72 females and 56 males) were treated, compared to 149 patients (78 females and 71 males) in 2021. A comparison of clinical manifestations revealed a reduction in symptoms such as fever, cough, dyspnea, sputum production, night sweats, weight loss, appetite loss, chest pain, and fatigue. Among these, appetite loss, fatigue, and hospitalizations due to TB showed statistically significant reductions. The hospitalization rate for TB patients decreased following the onset of the pandemic. No significant differences were observed in the relative frequency, gender distribution, or treatment completion rates between the two years. Additionally, TB incidence and prevalence remained unchanged, and COVID-19 had no impact on the age or gender distribution of TB patients.
Conclusion: The findings indicate a reduction in hospitalizations and certain clinical symptoms of TB during the COVID-19 pandemic, highlighting the need for greater attention to TB, particularly in cases involving other comorbidities.
References
1. Griffith DE, Kerr CM. Tuberculosis: disease of the past, disease of the present. J Perianesth Nurs 1996;11(4):240-5 [DOI:10.1016/S1089-9472(96)80023-2] [PMID]
2. Hazrati S, Khaligh N, Moeini A, Amani F, Barak M, Rahimi G, et al. Epidemiology of tuberculosis in Ardabil city from 2005 to 2010. J Health 2013;4(2):103-9. (Persian) [URL:]
3. Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis 2015;95(5):527-31 [DOI:10.1016/j.tube.2015.05.017] [PMID]
4. Wang X, He W, Lei J, Liu G, Huang F, Zhao Y. Impact of Covid-19 pandemic on pre-treatment delays, detection, and clinical characteristics of tuberculosis patients in Ningxia Hui Autonomous Region, China. Front Public Health 2021;9:644536 [DOI:10.3389/fpubh.2021.644536] [PMID] []
5. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the Covid-19 pandemic on the tuberculosis epidemic: a modelling analysis. EClinicalMedicine 2020;28:100603 [DOI:10.1016/j.eclinm.2020.100603] [PMID] []
6. Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. Epidemiology of tuberculosis and progress toward meeting global targets-worldwide, 2019. MMWR Morb Mortal Wkly Rep 2021;70(12):427-30 [DOI:10.15585/mmwr.mm7012a4] [PMID] []
7. Sharifi-Mood B, Alavi-Naini R, Metanat M. Tuberculosis and drug resistance in Iran. Zahedan J Res Med Sci 2010;12(3):1-6. (Persian) [URL:]
8. Saberifar R. Effective environmental and demographic factors on incidence of tuberculosis in Mashhad, Iran. J Mazandaran Univ Med Sci 2017;27(147):404-8. (Persian) [URL:]
9. Dizaji MK, Kazemnejad A, Tabarsi P, Zayeri F. Risk factors associated with survival of pulmonary tuberculosis. Iran J Public Health 2018;47(7):980-8 [PMID] [PMCID: PMC6119565]
10. Wani RL. Clinical manifestations of pulmonary and extra-pulmonary tuberculosis. South Sudan Med J 2013;6(3):52-6 [google scholar]
11. Soko RN, Burke RM, Feasey HR, Sibande W, Nliwasa M, Henrion MY, et al. Effects of coronavirus disease pandemic on tuberculosis notifications, Malawi. Emerg Infect Dis 2021;27(7):1831-40 [DOI:10.3201/eid2707.210557] [PMID] []
12. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L, et al. Collateral impact of the coronavirus disease 2019 (Covid-19) pandemic on tuberculosis control in Jiangsu Province, China. Emerg Infect Dis 2021;73(3):542-4 [DOI:10.1093/cid/ciaa1289] [PMID] []
13. Choi H, Ko Y, Lee C, Chung S, Kim H, Kim J, et al. Impact of Covid-19 on TB epidemiology in South Korea. Int J Tuberc Lung Dis 2021;25(10):854-60 [DOI:10.5588/ijtld.21.0255] [PMID]
14. Lai CC, Yu WL. The Covid-19 pandemic and tuberculosis in Taiwan. J Infect 2020;81(2):e159-61 [DOI:10.1016/j.jinf.2020.06.014] [PMID] []
15. Wang Q, Guo S, Wei X, Dong Q, Xu N, Li H, et al. Global prevalence, treatment and outcome of tuberculosis and Covid-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021). BMJ Open 2022;12(6):e059396 [DOI:10.1136/bmjopen-2021-059396] [PMID] []
16. McQuaid CF, Henrion MY, Burke RM, MacPherson P, Nzawa-Soko R, Horton KC. Inequalities in the impact of Covid-19-associated disruptions on tuberculosis diagnosis by age and sex in 45 high TB burden countries. BMC Med 2022;20(1):432 [DOI:10.1186/s12916-022-02624-6] [PMID] []
17. Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, et al. Increase in tuberculosis diagnostic delay during first wave of the Covid-19 pandemic: data from an Italian infectious disease referral hospital. Antibiotics (Basel) 2021;10(3):272 [DOI:10.3390/antibiotics10030272] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
